Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Praluent Self-Injection Possible from Sept. 1; Repatha Auto Mini Doser Approved
August 31, 2017
- Daiichi Sankyo Share Trade Halted after Report on AZ’s Acquisition Offer
August 31, 2017
- Trerief Filed for Parkinsonism in DLB: Sumitomo Dainippon
August 31, 2017
- MSD to Cut 250 Jobs as It Foresees Portfolio Changes
August 31, 2017
- Daiichi Sankyo’s DS-8201 Gets Breakthrough Therapy Designation
August 31, 2017
- Fujifilm Holdings Aims to Achieve 500 Billion Yen in Healthcare Sales in FY2019
August 31, 2017
- Mitsubishi Tanabe Chief Looks to Tap Canaglu’s CV Outcome Data to Boost Sales
August 30, 2017
- Boston Pharma Gets Rights to Daiichi Sankyo’s Preclinical RET Inhibitor
August 30, 2017
- BMS, Daiichi Sankyo to Collaborate on Opdivo-DS-8201 Combo
August 30, 2017
- Mitsubishi Tanabe to Create New Business by Fusing LLPs with Digital Technologies
August 30, 2017
- Takeda Divesting Laboratory Animal Unit amid R&D Realignment Drive
August 29, 2017
- Suzuken Group to Shed 350 Jobs as It Seeks SGA Efficiency
August 29, 2017
- FGF23 Antibody Burosumab Filed in US: Kyowa Kirin, Ultragenyx
August 28, 2017
- Poteligeo Earns FDA’s BT Designation for CTCL: Kyowa Kirin
August 28, 2017
- Spinraza to Hit Japan Market on August 30
August 28, 2017
- Astellas to Integrate Regenerative Medicine Research into US Unit
August 25, 2017
- Otsuka, Mylan Ink TB Deal for 29 Developing Countries
August 25, 2017
- Bayer Instruction Existed in Patient Info Acquisition, Sales Rep Tells Govt Panel
August 25, 2017
- Japan NDA Filed for Lymphoma Med Obinutuzumab: Chugai/Nippon Shinyaku
August 24, 2017
- CureApp to Begin Clinical Trial of Japan’s First “Treatment App” in October
August 24, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…